1,447 Shares in Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) Acquired by BNP Paribas Arbitrage SA
BNP Paribas Arbitrage SA bought a new stake in shares of Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 1,447 shares of the company’s stock, valued at approximately $38,000.
Several other hedge funds have also added to or reduced their stakes in the company. Citigroup Inc. purchased a new position in Y-mAbs Therapeutics in the 4th quarter worth approximately $37,000. Strs Ohio purchased a new position in Y-mAbs Therapeutics in the 4th quarter worth approximately $38,000. American International Group Inc. purchased a new position in Y-mAbs Therapeutics in the 4th quarter worth approximately $93,000. Bank of America Corp DE raised its holdings in Y-mAbs Therapeutics by 3,056.5% in the 4th quarter. Bank of America Corp DE now owns 6,029 shares of the company’s stock worth $122,000 after acquiring an additional 5,838 shares during the last quarter. Finally, Deutsche Bank AG purchased a new position in Y-mAbs Therapeutics in the 4th quarter worth approximately $191,000. Hedge funds and other institutional investors own 24.80% of the company’s stock.
YMAB has been the subject of a number of recent analyst reports. HC Wainwright initiated coverage on shares of Y-mAbs Therapeutics in a report on Monday, April 1st. They issued a “buy” rating and a $36.00 price objective for the company. Zacks Investment Research upgraded shares of Y-mAbs Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, March 15th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $30.80.
Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings data on Friday, March 22nd. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.11). Sell-side analysts expect that Y-mAbs Therapeutics, Inc will post -1.95 earnings per share for the current fiscal year.
In other Y-mAbs Therapeutics news, insider Thomas Gad sold 250,000 shares of the business’s stock in a transaction on Thursday, April 11th. The shares were sold at an average price of $25.89, for a total transaction of $6,472,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last quarter, insiders have sold 270,000 shares of company stock valued at $6,888,700.
ILLEGAL ACTIVITY WARNING: “1,447 Shares in Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) Acquired by BNP Paribas Arbitrage SA” was published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.dailypolitical.com/2019/06/13/1447-shares-in-y-mabs-therapeutics-inc-nasdaqymab-acquired-by-bnp-paribas-arbitrage-sa.html.
Y-mAbs Therapeutics Profile
Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.
Recommended Story: What is a Special Dividend?
Want to see what other hedge funds are holding YMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Y-mAbs Therapeutics, Inc (NASDAQ:YMAB).
Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.